A risk score based on real-world data to predict early death in acute promyelocytic leukemia
Albin Österroos,
Tânia Maia,
Anna Eriksson,
Martin Jädersten,
Vladimir Lazarevic,
Lovisa Wennström,
Petar Antunovic,
Jörg Cammenga,
Stefan Deneberg,
Fryderyk Lorenz,
Lars Möllgård,
Bertil Uggla,
Emma Ölander,
Eliana Aguiar,
Fernanda Trigo,
Martin Höglund,
Gunnar Juliusson,
Sören Lehmann
Affiliations
Albin Österroos
Department of Medical Sciences, Uppsala University, Uppsala
Tânia Maia
Department of Clinical Hematology, University Hospital Center of São João, Porto
Anna Eriksson
Department of Medical Sciences, Uppsala University, Uppsala
Martin Jädersten
Department of Hematology, Karolinska University Hospital, Stockholm
Vladimir Lazarevic
Department of Hematology, Skåne University Hospital, Lund, Sweden; Stem Cell Center, Department of Hematology, Department of Laboratory Medicine, Lund University, Lund
Lovisa Wennström
Department of Hematology, Sahlgrenska University Hospital, Gothenburg
Petar Antunovic
Department of Hematology, Linköping University Hospital, Linköping
Jörg Cammenga
Department of Hematology, Linköping University Hospital, Linköping
Stefan Deneberg
Department of Hematology, Karolinska University Hospital, Stockholm
Fryderyk Lorenz
Department of Hematology, Norrland University Hospital, Umeå
Lars Möllgård
Department of Hematology, Sahlgrenska University Hospital, Gothenburg
Bertil Uggla
Department of Medicine, Division of Hematology, Örebro University Hospital, Örebro
Emma Ölander
Department of Hematology, Sundsvall Hospital, Sundsvall
Eliana Aguiar
Department of Clinical Hematology, University Hospital Center of São João, Porto
Fernanda Trigo
Department of Clinical Hematology, University Hospital Center of São João, Porto
Martin Höglund
Department of Medical Sciences, Uppsala University, Uppsala
Gunnar Juliusson
Department of Hematology, Skåne University Hospital, Lund, Sweden; Stem Cell Center, Department of Hematology, Department of Laboratory Medicine, Lund University, Lund
Sören Lehmann
Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Department of Hematology, Karolinska University Hospital, Stockholm
With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim was to develop a score that predicts the risk of ED in a real-life setting. We used APL patients in the populationbased Swedish AML Registry (n=301) and a Portuguese hospital-based registry (n=129) as training and validation cohorts, respectively. The cohorts were comparable with respect to age (median, 54 and 53 years) and ED rate (19.6% and 18.6%). The score was developed by logistic regression analyses, risk-per-quantile assessment and scoring based on ridge regression coefficients from multivariable penalized logistic regression analysis. White blood cell count, platelet count and age were selected by this approach as the most significant variables for predicting ED. The score identified low-, high- and very high-risk patients with ED risks of 4.8%, 20.2% and 50.9% respectively in the training cohort and with 6.7%, 25.0% and 36.0% as corresponding values for the validation cohort. The score identified an increased risk of ED already at sub-normal and normal white blood cell counts and, consequently, it was better at predicting ED risk than the Sanz score (AUROC 0.77 vs. 0.64). In summary, we here present an externally validated and population-based risk score to predict ED risk in a real-world setting, identifying patients with the most urgent need of aggressive ED prevention. The results also suggest that increased vigilance for ED is already necessary at sub-normal/normal white blood cell counts.